Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTRA1 | Q92743 | 1/20 | 0.43 |
| ▸ | CFD | P00746 | 5/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.35 |
| ▸ | XIAP | P98170 | 2/20 | 0.34 |
| ▸ | BIRC3 | Q13489 | 2/20 | 0.34 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29820379 | 1.00 | HTRA1 (0.43) | HTRA1CFDMCL1XIAPBIRC3 | |
| SCHEMBL29230924 | 1.00 | HTRA1 (0.43) | HTRA1CFDMCL1XIAPBIRC3 | |
| SCHEMBL29230917 | 1.00 | HTRA1 (0.43) | HTRA1CFDMCL1XIAPBIRC3 | |
| SCHEMBL29230921 | 1.00 | HTRA1 (0.43) | HTRA1CFDMCL1XIAPBIRC3 | |
| SCHEMBL29230725 | 0.92 | HTRA1 (0.43) | HTRA1CFDMCL1XIAPBIRC3 | |
| SCHEMBL29230729 | 0.92 | HTRA1 (0.43) | HTRA1CFDMCL1XIAPBIRC3 | |
| SCHEMBL24666767 | 0.92 | HTRA1 (0.43) | HTRA1CFDMCL1XIAPBIRC3 | |
| SCHEMBL29230730 | 0.92 | HTRA1 (0.43) | HTRA1CFDMCL1XIAPBIRC3 | |
| SCHEMBL29820388 | 0.92 | HTRA1 (0.43) | HTRA1CFDMCL1XIAPBIRC3 | |
| SCHEMBL24666768 | 0.89 | HTRA1 (0.43) | HTRA1CFDMCL1CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059665-A1 | DIMERIC COMPOUNDS AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2022198196-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS2, GYS1, PYGL | HTRA1 4038/4885CFD 4871/4885MCL1 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.